Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma (2014)
- Authors:
- Autor USP: SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1371/journal.pone.0095843
- Subjects: PROTEÍNAS QUINASES (GENÉTICA); PROTEÍNAS PROTO-ONCOGÊNICAS (GENÉTICA); EXPRESSÃO GÊNICA; OSTEOSSARCOMA
- Language: Inglês
- Imprenta:
- Publisher place: San Francisco
- Date published: 2014
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
MARTIN, Jeffrey W et al. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLOS ONE, v. 9, n. 5, p. e95843-1 - e95843-8, 2014Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0095843. Acesso em: 28 dez. 2025. -
APA
Martin, J. W., Chilton-MacNeill, S., Koti, M., Wijnen, A. J. van, Squire, J. A., & Zielenska, M. (2014). Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLOS ONE, 9( 5), e95843-1 - e95843-8. doi:10.1371/journal.pone.0095843 -
NLM
Martin JW, Chilton-MacNeill S, Koti M, Wijnen AJ van, Squire JA, Zielenska M. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma [Internet]. PLOS ONE. 2014 ; 9( 5): e95843-1 - e95843-8.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1371/journal.pone.0095843 -
Vancouver
Martin JW, Chilton-MacNeill S, Koti M, Wijnen AJ van, Squire JA, Zielenska M. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma [Internet]. PLOS ONE. 2014 ; 9( 5): e95843-1 - e95843-8.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1371/journal.pone.0095843 - Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
- Extracellular vesicles: evolving factors in stem cell biology
- The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Application of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting PTEN loss in diagnostic prostate cancer needle biopsies
- In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in sity hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
Informações sobre o DOI: 10.1371/journal.pone.0095843 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
